IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+0.65%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$560M
AUM Growth
+$560M
(-17%)
Cap. Flow
-$113M
Cap. Flow
% of AUM
-20.13%
Top 10 Holdings %
Top 10 Hldgs %
31.32%
Holding
256
New
15
Increased
27
Reduced
52
Closed
40
Top Buys
| 1 |
Biogen
BIIB
|
$41.6M |
| 2 |
CRISPR Therapeutics
CRSP
|
$16.9M |
| 3 |
Alector
ALEC
|
$8.69M |
| 4 |
Cullinan Oncology
CGEM
|
$7.59M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$6.31M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$27.4M |
| 2 |
IMAB
I-MAB
IMAB
|
$17.1M |
| 3 |
Tempest Therapeutics
TPST
|
$14.1M |
| 4 |
Curis
CRIS
|
$13.8M |
| 5 |
Prothena Corp
PRTA
|
$11M |
Sector Composition
| 1 | Healthcare | 96.31% |
| 2 | Technology | 0.53% |
| 3 | Consumer Staples | 0.24% |
| 4 | Financials | 0.14% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$19.4B
| $43.6M | 3.53% | 125,962 +120,262 | +2,110% | +$41.6M |
|
|
2
CRISPR Therapeutics
CRSP
$4.71B
| $19.4M | 1.57% | 119,711 +104,627 | +694% | +$16.9M |
|
3
X4 Pharmaceuticals
XFOR
$84.2M
| $17.7M | 1.43% | 2,719,290 +104,302 | +4% | +$678K |
|
|
TCON
4
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $17.6M | 1.43% | 2,716,840 | – | – |
|
|
5
Alector
ALEC
$238M
| $14.1M | 1.14% | 674,723 +417,223 | +162% | +$8.69M |
|
6
Galapagos
GLPG
$2.07B
| $13.9M | 1.12% | 200,000 | – | – |
|
|
CMRX
7
DELISTED
Chimerix, Inc.
CMRX
| $12.6M | 1.02% | 1,575,916 -21,598 | -1% | -$173K |
|
8
MacroGenics
MGNX
$112M
| $12.3M | 1% | 459,602 -40,867 | -8% | -$1.1M |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $12.2M | 0.99% | 365,544 -230,746 | -39% | -$7.72M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $11.9M | 0.96% | 640,606 +30 | +0% | +$559 |
|
11
Milestone Pharmaceuticals
MIST
$156M
| $10.9M | 0.88% | 1,980,400 +143,855 | +8% | +$791K |
|
|
SRRA
12
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $10.6M | 0.86% | 545,002 +99,814 | +22% | +$1.95M |
|
13
Vaxcyte
PCVX
$4B
| $10.1M | 0.82% | 448,110 -53,000 | -11% | -$1.19M |
|
14
Relmada Therapeutics
RLMD
$37.2M
| $9.61M | 0.78% | 300,207 +10,000 | +3% | +$320K |
|
|
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.43M | 0.76% | 230,889 -100,100 | -30% | -$4.09M |
|
|
AUTL
16
Autolus Therapeutics
AUTL
$399M
| $9M | 0.73% | 1,356,048 +100,000 | +8% | +$664K |
|
17
Annovis Bio
ANVS
$45M
| $8.86M | 0.72% | 103,527 -89,841 | -46% | -$7.69M |
|
18
Gossamer Bio
GOSS
$562M
| $8.51M | 0.69% | 1,048,383 | – | – |
|
19
Cabaletta Bio
CABA
$133M
| $8.15M | 0.66% | 947,128 +557,744 | +143% | +$4.8M |
|
|
20
Cullinan Oncology
CGEM
$445M
| $7.61M | 0.62% | 295,596 +294,596 | +29,460% | +$7.59M |
|
|
ODT
21
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $6.93M | 0.56% | 1,986,412 +650,000 | +49% | +$2.27M |
|
22
scPharmaceuticals
SCPH
$295M
| $6.69M | 0.54% | 1,095,024 -213,675 | -16% | -$1.31M |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.55M | 0.53% | 1,129,473 +450,000 | +66% | +$2.61M |
|
|
CCXI
24
DELISTED
ChemoCentryx, Inc.
CCXI
| $6.31M | 0.51% | +471,376 | New | +$6.31M |
|
25
Ocular Therapeutix
OCUL
$2.12B
| $5.95M | 0.48% | 419,573 | – | – |
|